Zyrtec-D OTC switch gets FDA approval

Johnson & Johnson's McNeil Consumer Healthcare subsidiary could launch Zyrtec-D behind the counter before the end of the year. FDA approved the antihistamine and nasal decongestant for nonprescription use in adults and children 12 years and older Nov. 9. Zyrtec-D (cetirizine HCl 5 mg and pseudoephedrine HCl 120 mg) has been available as a prescription drug since 2001. Under the Combat Meth Act, Zyrtec-D is required to be sold behind the counter because it contains pseudoephedrine, according to McNeil. J&J acquired OTC licensing rights for Zyrtec when it purchased Pfizer Consumer Healthcare in 2006...